Figure 3.

Observed PTPRT/PTPRD genetic alterations and bevacizumab response. Detected variants in the genes PTPRT (A) and PTPRD (B) are depicted according to their protein localization and were classified according to the observed variant type as splice-site variants, frameshift variants, and missense variants with or without COSMIC ID. A PTPRD missense variant (E1619K) and a PTPRD splice variant were observed in the same patient. PTPRT/PTPRD variants and PTPRD copy number loss are depicted in an oncoprint plot, with patients grouped according to bevacizumab response status (C). Maximum tumor lesion changes from baseline and PTPRT/PTPRD genetic alterations are displayed in a waterfall plot (D). The presence or absence of postulated deleterious PTPRT/PTPRD genetic alterations—including mutations and copy number losses—among responders and non-responders was analyzed by the Fisher’s exact test.